8-OH-PBZI

Iz Wikipedije, slobodne enciklopedije
Idi na navigaciju Idi na pretragu
8-OH-PBZI
(IUPAC) ime
(3aS,9bR)-3-propil-1,2,3a,4,5,9b-heksahidrobenzo[e]indol-8-ol
Klinički podaci
Identifikatori
ATC kod nije dodeljen
PubChem[1][2] 10353845
ChemSpider[3] 8529297
Hemijski podaci
Formula C15H21NO 
Mol. masa 231,333 g/mol
SMILES eMolekuli & PubHem
Farmakoinformacioni podaci
Trudnoća ?
Pravni status

8-OH-PBZI je lek koji se koristi u naučnim istraživanjima. On deluje kao potentan i selektivan agonist dopaminskog D3 receptora.[4][5][6]

Reference[uredi - уреди | uredi izvor]

  1. Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. http://www.sciencedirect.com/science/article/pii/S1359644610007737.  edit
  2. Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1. 
  3. Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. http://www.jcheminf.com/content/2/1/3.  edit
  4. Scheideler, MA; Martin, J; Hohlweg, R; Rasmussen, JS; Naerum, L; Ludvigsen, TS; Larsen, PJ; Korsgaard, N i dr.. (1997). „The preferential dopamine D3 receptor agonist cis-8-OH-PBZI induces limbic Fos expression in rat brain”. European journal of pharmacology 339 (2–3): 261–70. DOI:10.1016/S0014-2999(97)01372-1. PMID 9473144. 
  5. Fink-Jensen, A; Nielsen, EB; Hansen, L; Scheideler, MA (1998). „Behavioral and neurochemical effects of the preferential dopamine D3 receptor agonist cis-8-OH-PBZI”. European journal of pharmacology 342 (2–3): 153–61. DOI:10.1016/S0014-2999(97)01494-5. PMID 9548380. 
  6. Malik, P; Andersen, MB; Peacock, L (2004). „The effects of dopamine D3 agonists and antagonists in a nonhuman primate model of tardive dyskinesia”. Pharmacology, biochemistry, and behavior 78 (4): 805–10. DOI:10.1016/j.pbb.2004.05.019. PMID 15301939.